High-dose intravenous melphalan in a patient with multiple myeloma and oliguric renal failure

Clin Investig. 1994 Jul;72(7):522-5. doi: 10.1007/BF00207482.

Abstract

A kappa light-chain myeloma was diagnosed as the underlying disease in a 52-year-old woman with acute oliguric renal failure. The patient was erroneously treated with high-dose intravenous melphalan (60 mg/m2). Because of this overdose treatment with granulocyte colony-stimulating factor was initiated, but pronounced absolute leukopenia (white blood cell count < 0.5 x 10(9)/l) developed and lasted for 13 days. Following melphalan treatment a continuous increase in urine volume was accompanied by a decrease of serum creatinine and blood urea nitrogen. Within 10 days after the administration of melphalan the patient no longer required hemodialysis. We conclude that high-dose chemotherapy in combination with hematopoietic growth factors should be considered in individual cases with newly diagnosed light-chain nephropathy.

Publication types

  • Case Reports

MeSH terms

  • Acute Kidney Injury / complications
  • Acute Kidney Injury / drug therapy*
  • Dose-Response Relationship, Drug
  • Drug Overdose
  • Female
  • Humans
  • Injections, Intravenous
  • Melphalan / administration & dosage*
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Oliguria / drug therapy*
  • Oliguria / etiology
  • Renal Dialysis

Substances

  • Melphalan